B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1

REACTOME PATHWAY
Reactome: R-HSA-13623002 genes27 compounds

The Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 pathway (Reactome ID: R-HSA-1362300) involves 2 genes and is affected by 27 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.

Genes in this Pathway

CDK1HDAC1

Compounds Affecting Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1

#CompoundTargets HitStudies
1kenpaullone8
2alsterpaullone12
3indirubin300
4Clofibrate299
5Fenofibrate297
6Sertraline1,000
7Cinnarizine299
8Clotrimazole296
9Rotenone300
10Apigenin 5,7,4'-trihydroxy-flavone,300
11chrysin300
12fisetin78
13Luteolin 5,7,3',4'-tetrahydroxy-flavone,150
14Quercetin300
15Sorafenib300
16sp600125117
17Vorinostat299
18trichostatic acid [Supplementary Concept] related to trichostatin300
19scriptaid53
20Valproic Acid296
21pictilisib25
22Butyric Acid300
23Ursolic Acid300
24Celecoxib295
25Daunorubicin298
26Bortezomib300
27Camptothecin300

About the Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 Pathway

The Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 pathway is catalogued in Reactome (ID: R-HSA-1362300) and involves 2 genes. In the BiohacksAI corpus, 27 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include CDK1, HDAC1.